Upgrades Neutral Buy X

ARRY Array Tech

Guggenheim

$10

Downgrades Buy Neutral X

ARRY Array Tech

Seaport Research Partners

Reiterated Hold X

ARRY Array Tech

TD Cowen

$10 $7

Upgrades Underperform Neutral X

ARRY Array Tech

Exane BNP Paribas

$9

Downgrades Positive Neutral X

ARRY Array Tech

Susquehanna

$7

Reiterated Hold X

ARRY Array Tech

TD Cowen

$11.50 $10

Downgrades Buy Neutral X

ARRY Array Tech

BofA Securities

$11 $7

Downgrades Buy Neutral X

ARRY Array Tech

Guggenheim

Resumed Buy X

ARRY Array Tech

Jefferies

$11

Downgrades Buy Neutral X

ARRY Array Tech

ROTH MKM

$20 $8

Reiterated Hold X

ARRY Array Tech

TD Cowen

$16.50 $11.50

Upgrades Neutral Buy X

ARRY Array Tech

Citigroup

$17 $14

Initiated Positive X

ARRY Array Tech

Susquehanna

$14

Upgrades Perform Outperform X

ARRY Array Tech

Oppenheimer

$20

Upgrades Eq Weight Overweight X

ARRY Array Tech

Barclays

$15 $18

Initiated Market Perform X

ARRY Array Tech

BMO Capital Markets

$16

Initiated Sector Weight X

ARRY Array Tech

KeyBanc Capital Markets

Downgrades Neutral Underperform X

ARRY Array Tech

Exane BNP Paribas

$12

Reiterated Market Perform X

ARRY Array Tech

TD Cowen

$22.50 $16.50

Downgrades Overweight Eq Weight X

ARRY Array Tech

Barclays

$22 $15

Downgrades Overweight Eq Weight X

ARRY Array Tech

Wells Fargo

$22 $19

Downgrades Overweight Neutral X

ARRY Array Tech

Piper Sandler

$26 $22

Initiated Hold X

ARRY Array Tech

Jefferies

$18

Initiated Neutral X

ARRY Array Tech

Mizuho

$19

Initiated Neutral X

ARRY Array Tech

Exane BNP Paribas

$21

Initiated Buy X

ARRY Array Tech

Janney

$37

Initiated Buy X

ARRY Array Tech

Seaport Research Partners

$30

Initiated Outperform X

ARRY Array Tech

Wolfe Research

$25

Resumed Underweight X

ARRY Array Tech

Morgan Stanley

$16 $17

Upgrades Hold Buy X

ARRY Array Tech

Truist

$26

Initiated Neutral X

ARRY Array Tech

Citigroup

$24

Initiated Sector Outperform X

ARRY Array Tech

Scotiabank

$26

Initiated Overweight X

ARRY Array Tech

Cantor Fitzgerald

$26

Initiated Overweight X

ARRY Array Tech

Wells Fargo

$28

Upgrades Neutral Overweight X

ARRY Array Tech

Piper Sandler

$20 $28

Downgrades Eq-Weight Underweight X

ARRY Array Tech

Morgan Stanley

$17 $15

Initiated Overweight X

ARRY Array Tech

Barclays

$20

Upgrades Neutral Buy X

ARRY Array Tech

ROTH Capital

Initiated Outperform X

ARRY Array Tech

Northland Capital

$18

Downgrades Buy Neutral X

ARRY Array Tech

ROTH Capital

$25 $7

Resumed Hold X

ARRY Array Tech

Truist

$14

Resumed Neutral X

ARRY Array Tech

Guggenheim

Downgrades Buy Neutral X

ARRY Array Tech

Guggenheim

Initiated Hold X

ARRY Array Tech

Truist

$23

Upgrades Underweight Eq Weight X

ARRY Array Tech

Barclays

$15

Resumed Outperform X

ARRY Array Tech

Credit Suisse

$31

Upgrades Neutral Outperform X

ARRY Array Tech

Credit Suisse

$42 $31

Downgrades Overweight Underweight X

ARRY Array Tech

Barclays

$32 $16

Reiterated Market Perform X

ARRY Array Tech

Cowen

$45.50 $24

Downgrades Overweight Neutral X

ARRY Array Tech

Piper Sandler

$53 $27

Downgrades Buy Neutral X

ARRY Array Tech

ROTH Capital

$53 $25

Upgrades Eq Weight Overweight X

ARRY Array Tech

Barclays

Upgrades Neutral Buy X

ARRY Array Tech

UBS

$43

Upgrades Underweight Eq-Weight X

ARRY Array Tech

Morgan Stanley

$30

Upgrades Accumulate Buy X

ARRY Array Tech

Johnson Rice

$50

Initiated Accumulate X

ARRY Array Tech

Johnson Rice

$57

Initiated Overweight X

ARRY Array Tech

Piper Sandler

$60

Initiated Outperform X

ARRY Array Biopharma

Leerink Partners

$28

Initiated Neutral X

ARRY Array Biopharma

Goldman

$20

Reiterated Buy X

ARRY Array Biopharma

Stifel

$20 $23

ARRY  Array BioPharma Inc.

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.